145 related articles for article (PubMed ID: 30629434)
1. Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy.
Chen Y; Yuan X; Zhang W; Tang M; Zheng L; Wang F; Yan W; Yang S; Wei Y; He J; Chen L
J Med Chem; 2019 Feb; 62(3):1577-1592. PubMed ID: 30629434
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Yang Z; Shen M; Tang M; Zhang W; Cui X; Zhang Z; Pei H; Li Y; Hu M; Bai P; Chen L
Eur J Med Chem; 2019 Sep; 178():116-130. PubMed ID: 31177073
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
Zhang M; Wei W; Peng C; Ma X; He X; Zhang H; Zhou M
Bioorg Med Chem Lett; 2021 Oct; 49():128286. PubMed ID: 34314844
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Thieno[2,3-
Pan Z; Li X; Wang Y; Jiang Q; Jiang L; Zhang M; Zhang N; Wu F; Liu B; He G
J Med Chem; 2020 Apr; 63(7):3678-3700. PubMed ID: 32153186
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
Liang X; Zang J; Li X; Tang S; Huang M; Geng M; Chou CJ; Li C; Cao Y; Xu W; Liu H; Zhang Y
J Med Chem; 2019 Apr; 62(8):3898-3923. PubMed ID: 30901208
[TBL] [Abstract][Full Text] [Related]
6. Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors.
Mohamed MFA; Youssif BGM; Shaykoon MSA; Abdelrahman MH; Elsadek BEM; Aboraia AS; Abuo-Rahma GEA
Bioorg Chem; 2019 Oct; 91():103127. PubMed ID: 31374527
[TBL] [Abstract][Full Text] [Related]
7. CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
Singh A; Chang TY; Kaur N; Hsu KC; Yen Y; Lin TE; Lai MJ; Lee SB; Liou JP
Eur J Med Chem; 2021 Apr; 215():113169. PubMed ID: 33588178
[TBL] [Abstract][Full Text] [Related]
8. Optimization of 4,6-Disubstituted Pyrido[3,2-
Han Y; Zhang H; Wang S; Li B; Xing K; Shi Y; Cao H; Zhang J; Tong T; Zang J; Guan L; Gao X; Wang Y; Liu D; Huang M; Jing Y; Zhao L
J Med Chem; 2021 Sep; 64(18):13719-13735. PubMed ID: 34515481
[TBL] [Abstract][Full Text] [Related]
9. Discovery and SARs of 5-Chloro-
Wang Y; Chen X; Yan Y; Zhu X; Liu M; Liu X
J Med Chem; 2020 Mar; 63(6):3327-3347. PubMed ID: 32129996
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel 1,2,3,4-Tetrahydrobenzofuro[2,3-
Lai Z; Ni H; Hu X; Cui S
J Med Chem; 2023 Aug; 66(15):10791-10807. PubMed ID: 37498552
[TBL] [Abstract][Full Text] [Related]
11. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.
Yao D; Jiang J; Zhang H; Huang Y; Huang J; Wang J
Bioorg Med Chem Lett; 2021 Sep; 47():128204. PubMed ID: 34139324
[TBL] [Abstract][Full Text] [Related]
13. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Gaudio E; Tarantelli C; Ponzoni M; Odore E; Rezai K; Bernasconi E; Cascione L; Rinaldi A; Stathis A; Riveiro E; Cvitkovic E; Zucca E; Bertoni F
Oncotarget; 2016 Sep; 7(36):58142-58147. PubMed ID: 27494885
[TBL] [Abstract][Full Text] [Related]
14. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
16. Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents.
Peng X; Chen J; Li L; Sun Z; Liu J; Ren Y; Huang J; Chen J
J Med Chem; 2021 Jun; 64(12):8447-8473. PubMed ID: 34097389
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
[TBL] [Abstract][Full Text] [Related]
18. Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.
Peng FW; Wu TT; Ren ZW; Xue JY; Shi L
Bioorg Med Chem Lett; 2015 Nov; 25(22):5137-41. PubMed ID: 26475519
[TBL] [Abstract][Full Text] [Related]
19. Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
Yun F; Cheng C; Ullah S; He J; Zahi MR; Yuan Q
Eur J Med Chem; 2019 Aug; 176():195-207. PubMed ID: 31103900
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]